<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32284379</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>21</Day></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>Novel Ionophores Active against La Crosse Virus Identified through Rapid Antiviral Screening.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e00086-20</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.00086-20</ELocationID><Abstract><AbstractText>Bunyaviruses are significant human pathogens, causing diseases ranging from hemorrhagic fevers to encephalitis. Among these viruses, La Crosse virus (LACV), a member of the California serogroup, circulates in the eastern and midwestern United States. While LACV infection is often asymptomatic, dozens of cases of encephalitis are reported yearly. Unfortunately, no antivirals have been approved to treat LACV infection. Here, we developed a method to rapidly test potential antivirals against LACV infection. From this screen, we identified several potential antiviral molecules, including known antivirals. Additionally, we identified many novel antivirals that exhibited antiviral activity without affecting cellular viability. Valinomycin, a potassium ionophore, was among our top targets. We found that valinomycin exhibited potent anti-LACV activity in multiple cell types in a dose-dependent manner. Valinomycin did not affect particle stability or infectivity, suggesting that it may preclude virus replication by altering cellular potassium ions, a known determinant of LACV entry. We extended these results to other ionophores and found that the antiviral activity of valinomycin extended to other viral families, including bunyaviruses (Rift Valley fever virus, Keystone virus), enteroviruses (coxsackievirus, rhinovirus), flavirivuses (Zika virus), and coronaviruses (human coronavirus 229E [HCoV-229E] and Middle East respiratory syndrome CoV [MERS-CoV]). In all viral infections, we observed significant reductions in virus titer in valinomycin-treated cells. In sum, we demonstrate the importance of potassium ions to virus infection, suggesting a potential therapeutic target to disrupt virus replication.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 American Society for Microbiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sandler</LastName><ForeName>Zachary J</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease and Immunology Research Institute, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Firpo</LastName><ForeName>Mason R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omoba</LastName><ForeName>Oreoluwa S</ForeName><Initials>OS</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease and Immunology Research Institute, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vu</LastName><ForeName>Michelle N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menachery</LastName><ForeName>Vineet D</ForeName><Initials>VD</Initials><Identifier Source="ORCID">0000-0001-8803-7606</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Human Infections and Immunity, University of Texas Medical Branch at Galveston, Galveston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mounce</LastName><ForeName>Bryan C</ForeName><Initials>BC</Initials><Identifier Source="ORCID">0000-0003-1710-5362</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA bmounce@luc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease and Immunology Research Institute, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI100625</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007476">Ionophores</NameOfSubstance></Chemical><Chemical><RegistryNumber>2001-95-8</RegistryNumber><NameOfSubstance UI="D014634">Valinomycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWP5GA015D</RegistryNumber><NameOfSubstance UI="D011188">Potassium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004670" MajorTopicYN="N">Encephalitis, California</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005416" MajorTopicYN="N">Flavivirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007476" MajorTopicYN="N">Ionophores</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018062" MajorTopicYN="N">La Crosse virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016851" MajorTopicYN="N">Orthobunyavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011188" MajorTopicYN="N">Potassium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014634" MajorTopicYN="N">Valinomycin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">La Crosse virus</Keyword><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">bunyaviruses</Keyword><Keyword MajorTopicYN="N">ionophores</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32284379</ArticleId><ArticleId IdType="pmc">PMC7269492</ArticleId><ArticleId IdType="doi">10.1128/AAC.00086-20</ArticleId><ArticleId IdType="pii">AAC.00086-20</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wikan N, Smith DR. 2016. Zika virus: history of a newly emerging arbovirus. Lancet Infect Dis 16:e119&#x2013;e126. doi:10.1016/S1473-3099(16)30010-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(16)30010-X</ArticleId><ArticleId IdType="pubmed">27282424</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L, Vaney M-C, Lavenir R, Pardigon N, Reynes J-M, Pettinelli F, Biscornet L, Diancourt L, Michel S, Duquerroy S, Guigon G, Frenkiel M-P, Br&#xe9;hin A-C, Cubito N, Despr&#xe8;s P, Kunst F, Rey FA, Zeller H, Brisse S. 2006. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med 3:e263. doi:10.1371/journal.pmed.0030263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0030263</ArticleId><ArticleId IdType="pmc">PMC1463904</ArticleId><ArticleId IdType="pubmed">16700631</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans AB, Peterson KE. 2019. Throw out the map: neuropathogenesis of the globally expanding California serogroup of orthobunyaviruses. Viruses 11:794. doi:10.3390/v11090794.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11090794</ArticleId><ArticleId IdType="pmc">PMC6784171</ArticleId><ArticleId IdType="pubmed">31470541</ArticleId></ArticleIdList></Reference><Reference><Citation>Westby KM, Fritzen C, Paulsen D, Poindexter S, Moncayo AC. 2015. La Crosse encephalitis virus infection in field-collected Aedes albopictus, Aedes japonicus, and Aedes triseriatus in Tennessee. J Am Mosq Control Assoc 31:233&#x2013;241. doi:10.2987/moco-31-03-233-241.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.2987/moco-31-03-233-241.1</ArticleId><ArticleId IdType="pubmed">26375904</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson BT, Brewster CC, Paulson SL. 2012. La Crosse virus infection alters blood feeding behavior in Aedes triseriatus and Aedes albopictus (Diptera: Culicidae). J Med Entomol 49:1424&#x2013;1429. doi:10.1603/ME12023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1603/ME12023</ArticleId><ArticleId IdType="pmc">PMC3551617</ArticleId><ArticleId IdType="pubmed">23270172</ArticleId></ArticleIdList></Reference><Reference><Citation>Bewick S, Agusto F, Calabrese JM, Muturi EJ, Fagan WF. 2016. Epidemiology of La Crosse virus emergence, Appalachia region, United States. Emerg Infect Dis 22:1921&#x2013;1929. doi:10.3201/eid2211.160308.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2211.160308</ArticleId><ArticleId IdType="pmc">PMC5088026</ArticleId><ArticleId IdType="pubmed">27767009</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. 2019. 
La Crosse encephalitis: epidemiology &amp; geographic distribution. https://www.cdc.gov/lac/tech/epi.html.</Citation></Reference><Reference><Citation>Curren EJ, Lehman J, Kolsin J, Walker WL, Martin SW, Staples JE, Hills SL, Gould CV, Rabe IB, Fischer M, Lindsey NP. 2018. West Nile virus and other nationally notifiable arboviral diseases: United States, 2017. MMWR Morb Mortal Wkly Rep 67:1137&#x2013;1142. doi:10.15585/mmwr.mm6741a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6741a1</ArticleId><ArticleId IdType="pmc">PMC6193690</ArticleId><ArticleId IdType="pubmed">30335737</ArticleId></ArticleIdList></Reference><Reference><Citation>Caplen H, Peters CJ, Bishop DH. 1985. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66:2271&#x2013;2277. doi:10.1099/0022-1317-66-10-2271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-66-10-2271</ArticleId><ArticleId IdType="pubmed">4045430</ArticleId></ArticleIdList></Reference><Reference><Citation>Faburay B, LaBeaud AD, McVey DS, Wilson WC, Richt JA. 2017. Current status of Rift Valley fever vaccine development. Vaccines 5:29. doi:10.3390/vaccines5030029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines5030029</ArticleId><ArticleId IdType="pmc">PMC5620560</ArticleId><ArticleId IdType="pubmed">28925970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikegami T. 2017. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate. Expert Rev Vaccines 16:601&#x2013;611. doi:10.1080/14760584.2017.1321482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2017.1321482</ArticleId><ArticleId IdType="pmc">PMC5658789</ArticleId><ArticleId IdType="pubmed">28425834</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese FS, Kaukinen P, Gl&#xe4;sker S, Bespalov M, Hanski L, Wennerberg K, K&#xfc;mmerer BM, Ahola T. 2016. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral Res 126:117&#x2013;124. doi:10.1016/j.antiviral.2015.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.12.012</ArticleId><ArticleId IdType="pubmed">26752081</ArticleId></ArticleIdList></Reference><Reference><Citation>Micewicz ED, Khachatoorian R, French SW, Ruchala P. 2018. Identification of novel small-molecule inhibitors of Zika virus infection. Bioorg Med Chem Lett 28:452&#x2013;458. doi:10.1016/j.bmcl.2017.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2017.12.019</ArticleId><ArticleId IdType="pubmed">29258771</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong S, Kang S, Dimopoulos G. 2019. Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. PLoS Negl Trop Dis 13:e0007681. doi:10.1371/journal.pntd.0007681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0007681</ArticleId><ArticleId IdType="pmc">PMC6716673</ArticleId><ArticleId IdType="pubmed">31430351</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, Galarza-Mu&#xf1;oz G, McGrath EL, Urrabaz-Garza R, Gao J, Wu P, Menon R, Saade G, Fernandez-Salas I, Rossi SL, Vasilakis N, Routh A, Bradrick SS, Garcia-Blanco MA. 2016. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe 20:259&#x2013;270. doi:10.1016/j.chom.2016.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2016.07.004</ArticleId><ArticleId IdType="pmc">PMC4993926</ArticleId><ArticleId IdType="pubmed">27476412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang Y, Li Y, Jasperson D, Henningson J, Lee J, Ma J, Li Y, Duff M, Liu H, Bai D, McVey S, Richt JA, Ikegami T, Wilson WC, Ma W. 2019. Identification and evaluation of antivirals for Rift Valley fever virus. Vet Microbiol 230:110&#x2013;116. doi:10.1016/j.vetmic.2019.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetmic.2019.01.027</ArticleId><ArticleId IdType="pubmed">30827375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou Z, Sun Y, Rao Z. 2014. Current progress in antiviral strategies. Trends Pharmacol Sci 35:86&#x2013;102. doi:10.1016/j.tips.2013.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2013.11.006</ArticleId><ArticleId IdType="pmc">PMC7112804</ArticleId><ArticleId IdType="pubmed">24439476</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Serradilla M, Risco C, Pacheco B. 2019. Drug repurposing for new, efficient, broad spectrum antivirals. Virus Res 264:22&#x2013;31. doi:10.1016/j.virusres.2019.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2019.02.011</ArticleId><ArticleId IdType="pmc">PMC7114681</ArticleId><ArticleId IdType="pubmed">30794895</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercorelli B, Pal&#xf9; G, Loregian A. 2018. Drug repurposing for viral infectious diseases: how far are we? Trends Microbiol 26:865&#x2013;876. doi:10.1016/j.tim.2018.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2018.04.004</ArticleId><ArticleId IdType="pmc">PMC7126639</ArticleId><ArticleId IdType="pubmed">29759926</ArticleId></ArticleIdList></Reference><Reference><Citation>Hover S, Foster B, Fontana J, Kohl A, Goldstein SAN, Barr JN, Mankouri J. 2018. Bunyavirus requirement for endosomal K+ reveals new roles of cellular ion channels during infection. PLoS Pathog 14:e1006845. doi:10.1371/journal.ppat.1006845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006845</ArticleId><ArticleId IdType="pmc">PMC5805358</ArticleId><ArticleId IdType="pubmed">29352299</ArticleId></ArticleIdList></Reference><Reference><Citation>Punch EK, Hover S, Blest HTW, Fuller J, Hewson R, Fontana J, Mankouri J, Barr JN. 2018. Potassium is a trigger for conformational change in the fusion spike of an enveloped RNA virus. J Biol Chem 293:9937&#x2013;9944. doi:10.1074/jbc.RA118.002494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.002494</ArticleId><ArticleId IdType="pmc">PMC6028977</ArticleId><ArticleId IdType="pubmed">29678879</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlton FW, Hover S, Fuller J, Hewson R, Fontana J, Barr JN, Mankouri J. 2019. Cellular cholesterol abundance regulates potassium accumulation within endosomes and is an important determinant in Bunyavirus entry. J Biol Chem 294:7335&#x2013;7347. doi:10.1074/jbc.RA119.007618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA119.007618</ArticleId><ArticleId IdType="pmc">PMC6509484</ArticleId><ArticleId IdType="pubmed">30804209</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BA, Hage A, Kalveram B, Mears M, Plante JA, Rodriguez SE, Ding Z, Luo X, Bente D, Bradrick SS, Freiberg AN, Popov V, Rajsbaum R, Rossi S, Russell WK, Menachery VD. 2019. Peptidoglycan-associated cyclic lipopeptide disrupts viral infectivity. J Virol 93:e01282-19. doi:10.1128/JVI.01282-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01282-19</ArticleId><ArticleId IdType="pmc">PMC6819921</ArticleId><ArticleId IdType="pubmed">31462558</ArticleId></ArticleIdList></Reference><Reference><Citation>Frugulhetti ICI, Rebello MA. 1989. Na+ and K+ Concentration and Regulation of Protein Synthesis in L-A9 and Aedes albopictus Cells Infected with Marituba Virus (Bunyaviridae). J Gen Virol 70:3493&#x2013;3499. doi:10.1099/0022-1317-70-12-3493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-70-12-3493</ArticleId><ArticleId IdType="pubmed">2607344</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukacs GL, Chang XB, Kartner N, Rotstein OD, Riordan JR, Grinstein S. 1992. The cystic fibrosis transmembrane regulator is present and functional in endosomes. Role as a determinant of endosomal pH. J Biol Chem 267:14568&#x2013;14572.</Citation><ArticleIdList><ArticleId IdType="pubmed">1378835</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TG, Goda FO, Navar GL, Campbell WC, Majewski RR, Galvan DL, Pontillon F, Kaysen JH, Goodwin TJ, Paddock SW, Verroust PJ. 1998. Membrane potential mediates H(+)-ATPase dependence of &#x201c;degradative pathway&#x201d; endosomal fusion. J Membr Biol 162:157&#x2013;167. doi:10.1007/s002329900353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002329900353</ArticleId><ArticleId IdType="pubmed">9538509</ArticleId></ArticleIdList></Reference><Reference><Citation>Matter AM, Hoot SB, Anderson PD, Neves SS, Cheng Y-Q. 2009. Valinomycin biosynthetic gene cluster in Streptomyces: conservation, ecology and evolution. PLoS One 4:e7194. doi:10.1371/journal.pone.0007194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0007194</ArticleId><ArticleId IdType="pmc">PMC2746310</ArticleId><ArticleId IdType="pubmed">19787052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C-Y, Jan J-T, Ma S-H, Kuo C-J, Juan H-F, Cheng Y-S, Hsu H-H, Huang H-C, Wu D, Brik A, Liang F-S, Liu R-S, Fang J-M, Chen S-T, Liang P-H, Wong C-H. 2004. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A 101:10012&#x2013;10017. doi:10.1073/pnas.0403596101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0403596101</ArticleId><ArticleId IdType="pmc">PMC454157</ArticleId><ArticleId IdType="pubmed">15226499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermejo M, L&#xf3;pez-Huertas MR, Garc&#xed;a-P&#xe9;rez J, Climent N, Descours B, Ambrosioni J, Mateos E, Rodr&#xed;guez-Mora S, Rus-Bercial L, Benkirane M, Mir&#xf3; JM, Plana M, Alcam&#xed; J, Coiras M. 2016. Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells. Biochem Pharmacol 106:30&#x2013;45. doi:10.1016/j.bcp.2016.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2016.02.002</ArticleId><ArticleId IdType="pubmed">26851491</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wispelaere M, LaCroix AJ, Yang PL. 2013. The small molecules AZD0530 and dasatinib inhibit Dengue virus RNA replication via Fyn kinase. J Virol 87:7367&#x2013;7381. doi:10.1128/JVI.00632-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00632-13</ArticleId><ArticleId IdType="pmc">PMC3700292</ArticleId><ArticleId IdType="pubmed">23616652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafuri Y, Takemori E, Oogose K, Inouye Y, Nakamura S, Kitahara Y, Nakahara S, Kubo A. 1988. Mechanism of inhibition of reverse transcriptase by quinone antibiotics. II. Dependence on putative quinone pocket on the enzyme molecule. J Antibiot (Tokyo) 41:1471&#x2013;1478. doi:10.7164/antibiotics.41.1471.</Citation><ArticleIdList><ArticleId IdType="doi">10.7164/antibiotics.41.1471</ArticleId><ArticleId IdType="pubmed">2461354</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung E, Lee J-Y, Kim HJ, Ryu C-K, Lee K-I, Kim M, Lee C-K, Go YY. 2018. Identification of quinone analogues as potential inhibitors of picornavirus 3C protease in vitro. Bioorg Med Chem Lett 28:2533&#x2013;2538. doi:10.1016/j.bmcl.2018.05.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2018.05.046</ArticleId><ArticleId IdType="pubmed">29866517</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikegami T, Won S, Peters CJ, Makino S. 2006. Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J Virol 80:2933&#x2013;2940. doi:10.1128/JVI.80.6.2933-2940.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.80.6.2933-2940.2006</ArticleId><ArticleId IdType="pmc">PMC1395455</ArticleId><ArticleId IdType="pubmed">16501102</ArticleId></ArticleIdList></Reference><Reference><Citation>Promsong A, Chuenchitra T, Saipin K, Tewtrakul S, Panichayupakaranant P, Satthakarn S, Nittayananta W. 2018. Ellagic acid inhibits HIV-1 infection in vitro: potential role as a novel microbicide. Oral Dis 24:249&#x2013;252. doi:10.1111/odi.12835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/odi.12835</ArticleId><ArticleId IdType="pubmed">29480632</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SW, Kwon MJ, Yoo JY, Choi H-J, Ahn Y-J. 2014. Antiviral activity and possible mode of action of ellagic acid identified in Lagerstroemia speciosa leaves toward human rhinoviruses. BMC Complement Altern Med 14:171. doi:10.1186/1472-6882-14-171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6882-14-171</ArticleId><ArticleId IdType="pmc">PMC4052798</ArticleId><ArticleId IdType="pubmed">24885569</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin MS, Kang EH, Lee YI. 2005. A flavonoid from medicinal plants blocks hepatitis B virus-e antigen secretion in HBV-infected hepatocytes. Antiviral Res 67:163&#x2013;168. doi:10.1016/j.antiviral.2005.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2005.06.005</ArticleId><ArticleId IdType="pubmed">16118024</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacau EP, Est&#xe9;vez-Braun A, Ravelo AG, Ferro EA, Tokuda H, Mukainaka T, Nishino H. 2003. Inhibitory effects of lapachol derivatives on Epstein-Barr virus activation. Bioorg Med Chem 11:483&#x2013;488. doi:10.1016/s0968-0896(02)00542-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0968-0896(02)00542-4</ArticleId><ArticleId IdType="pubmed">12538012</ArticleId></ArticleIdList></Reference><Reference><Citation>do Carmo Lagrota MH, Wigg MD, Aguiar AN, Pinto AV, Pinto Mdo C. 1986. Antiviral activity of naphthoquinones. I. Lapachol derivatives against enteroviruses. Rev Latinoam Microbiol 28:221&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">3035676</ArticleId></ArticleIdList></Reference><Reference><Citation>Berka U, Khan A, Blaas D, Fuchs R. 2009. Human rhinovirus type 2 uncoating at the plasma membrane is not affected by a pH gradient but is affected by the membrane potential. J Virol 83:3778&#x2013;3787. doi:10.1128/JVI.01739-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01739-08</ArticleId><ArticleId IdType="pmc">PMC2663288</ArticleId><ArticleId IdType="pubmed">19193784</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris MJ, Malhi M, Duan W, Ouyang H, Granados A, Cen Y, Tseng Y-C, Gubbay J, Maynes J, Moraes TJ. 2018. Targeting intracellular ion homeostasis for the control of respiratory syncytial virus. Am J Respir Cell Mol Biol 59:733&#x2013;744. doi:10.1165/rcmb.2017-0345OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2017-0345OC</ArticleId><ArticleId IdType="pubmed">30095982</ArticleId></ArticleIdList></Reference><Reference><Citation>Irurzun A, Carrasco L. 2001. Entry of poliovirus into cells is blocked by valinomycin and concanamycin A. Biochemistry 40:3589&#x2013;3600. doi:10.1021/bi002069p.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi002069p</ArticleId><ArticleId IdType="pubmed">11297425</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedows E, Hatfield GM. 1982. An investigation of the antiviral activity of Podophyllum peltatum. J Nat Prod 45:725&#x2013;729. doi:10.1021/np50024a015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/np50024a015</ArticleId><ArticleId IdType="pubmed">6298369</ArticleId></ArticleIdList></Reference><Reference><Citation>Biziagos E, Crance JM, Passagot J, Deloince R. 1987. Effect of antiviral substances on hepatitis A virus replication in vitro. J Med Virol 22:57&#x2013;66. doi:10.1002/jmv.1890220108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.1890220108</ArticleId><ArticleId IdType="pubmed">3035080</ArticleId></ArticleIdList></Reference><Reference><Citation>Min BS, Lee HK, Lee SM, Kim YH, Bae KH, Otake T, Nakamura N, Hattori M. 2002. Anti-human immunodeficiency virus-type 1 activity of constituents from Juglans mandshurica. Arch Pharm Res 25:441&#x2013;445. doi:10.1007/bf02976598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf02976598</ArticleId><ArticleId IdType="pubmed">12214852</ArticleId></ArticleIdList></Reference><Reference><Citation>Fesen MR, Kohn KW, Leteurtre F, Pommier Y. 1993. Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci U S A 90:2399&#x2013;2403. doi:10.1073/pnas.90.6.2399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.6.2399</ArticleId><ArticleId IdType="pmc">PMC46094</ArticleId><ArticleId IdType="pubmed">8460151</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng L, Dai P, Ciro A, Smee DF, Djaballah H, Shuman S. 2007. Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J Virol 81:13392&#x2013;13402. doi:10.1128/JVI.00770-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00770-07</ArticleId><ArticleId IdType="pmc">PMC2168821</ArticleId><ArticleId IdType="pubmed">17928345</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta A, Tsubuki M, Endoh M, Miyamoto T, Tanaka J, Salam KA, Akimitsu N, Tani H, Yamashita A, Moriishi K, Nakakoshi M, Sekiguchi Y, Tsuneda S, Noda N. 2015. Identification of hydroxyanthraquinones as novel inhibitors of hepatitis C virus NS3 helicase. Int J Mol Sci 16:18439&#x2013;18453. doi:10.3390/ijms160818439.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms160818439</ArticleId><ArticleId IdType="pmc">PMC4581254</ArticleId><ArticleId IdType="pubmed">26262613</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q, Hou J, Yang P, Yan J, Yu X, Zhuo Y, He S, Xu F. 2019. Antiviral activity of mitoxantrone dihydrochloride against human herpes simplex virus mediated by suppression of the viral immediate early genes. BMC Microbiol 19:274. doi:10.1186/s12866-019-1639-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-019-1639-8</ArticleId><ArticleId IdType="pmc">PMC6898960</ArticleId><ArticleId IdType="pubmed">31812160</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;se JR, St&#xfc;nzner D, Zirm M, Egger-B&#xfc;ssing C, Schmalzl F. 1980. Effect of aristolochic acid on herpes simplex infection of the rabbit eye. Arzneimittelforschung 30:1571&#x2013;1573. (In German.)</Citation><ArticleIdList><ArticleId IdType="pubmed">7193027</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>